Teva Announces FDA Acceptance of Reslizumab For Asthma – Lung Disease News


Lung Disease News

Teva Announces FDA Acceptance of Reslizumab For Asthma
Lung Disease News
Reslizumab is being developed as treatment of inadequately controlled asthma in adults and young people who have increased blood eosinophils, despite being under treatment with an inhaled corticosteroid (ICS) drug regimen. “Despite currently available …
FDA to review Teva asthma biologicBioPharma Dive
FDA will review Teva's asthma biologic reslizumabPharmaTimes
Stock Update (NYSE:TEVA): Teva Pharmaceuticals Industries Ltd (ADR Smarter Analyst
PMLiVE
all 20 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.